List view / Grid view
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
Scientists have developed a compound blend that reverses sugar-related cellular damage in mice, which could lead to future therapies to slow ageing and treat metabolic diseases.
Scientists have linked rare mutations in SPNS1 to a previously unknown lipid recycling pathway in lysosomes, revealing how faulty fat processing can trigger muscle and liver disease.
Scientists have discovered the molecular ‘switch’ that powers sperm for fertilisation, which could potentially lead to new infertility treatments.
A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential for long-lasting weight loss without regain.
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
In the fight against antibiotic-resistant bacteria, researchers at Michigan State University (MSU) have made a discovery that could change how we target deadly pathogens like Staphylococcus aureus and its drug-resistant strain - MRSA.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
Researchers have found that the GDF15 cytokine could have beneficial effects on the metabolism and reduce obesity.
